A practical reference on BDNF: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
== Genetics == The gene encoding the enzyme is referred to as DDC is located on chromosome 7 in humans. It consists of 15 exons encoding a protein of 480 amino acids. Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, for example, a one-base pair deletion at 601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder and autism. No direct correlation between gene variation and autism was found. More than 50 mutations of DDC have been correlated with AADC deficiency. This condition is most prevalent in Asia, presumably due to the founder effect. Alternative splicing events and promoters have been observed that lead to various forms of the AADC enzyme. Unique usage of certain promoters leads to transcription of only the first exon to produce an extra-neuronal isoform, and splicing of exon 3 leads to a product devoid of enzymatic activity. Analyses via porcine specimens have elucidated two AADC isoforms – resulting from exclusion of exon 5 and exons 5 and 6 – that lack a portion of the decarboxylating domain.
Another incident during the war highlighted the question of large-scale Iraqi combat deaths. This was the "bulldozer assault", where two brigades from the US 1st Infantry Division (Mechanized) were faced with a large and complex trench network, as part of the heavily fortified "Saddam Hussein Line". After some deliberation, they opted to use anti-mine plows mounted on tanks and combat earthmovers to simply plow over and bury alive the defending Iraqi soldiers. Not a single American was killed during the attack. Reporters were banned from witnessing the attack, near the neutral zone that touches the border between Saudi Arabia and Iraq. Every American in the assault was inside an armored vehicle. Patrick Day Sloyan of Newsday reported, "Bradley Fighting Vehicles and Vulcan armored carriers straddled the trench lines and fired into the Iraqi soldiers as the tanks covered them with mounds of sand. 'I came through right after the lead company,' [Col. Anthony] Moreno said. 'What you saw was a bunch of buried trenches with peoples' arms and things sticking out of them.'" After the war, the Iraqi government said that only 44 bodies were found. In his book The Wars Against Saddam, John Simpson alleges that US forces attempted to cover up the incident.
Xestospongia testudinaria is a species of barrel sponge in the family Petrosiidae. More commonly known as Giant Barrel Sponges, they have the basic structure of a typical sponge. Their body is made of a reticulation of cells aggregate on a siliceous scaffold composed of small spikes called spicules. Water is taken into the inner chamber of the sponge (known as the spongocoel) through ostia (small pores created by porocytes). Flagellated choanocytes line the inner chamber and help generate water currents through the sponge. Due to the amount of water that Great Barrel Sponges filter throughout their lifespan, they perform an important ecological role.
=== Irritable bowel syndrome === There is evidence that a dietician-supervised low-FODMAP diet is the best available way to control IBS symptoms, though there is a lack of evidence on possible adverse effects. The beneficial effect of low-FODMAP for people with IBS may be related to reduced osmotic load in the gut or changes in gut-brain axis signaling. The low-FODMAP diet does not cause any significant change in the gut microbiota in people with IBS. The effectiveness of low-FODMAP diet in children with IBS is unclear. While restrictive diets like the low-FODMAP diet can help manage symptoms in patients with Irritable bowel syndrome, they pose a significant danger: they can increase the patient's risk of developing disordered eating. The initial success in symptom reduction may become a dangerous obsession with controlling food, potentially leading to conditions such as ARFID or Orthorexia nervosa. These issues severely impact clinical outcomes and quality of life, and worsen overall health. Early monitoring and intervention are crucial to catching and addressing these pathological eating patterns.
Sources: en.wikipedia.org
==== Energy and the environment ==== Larson has introduced various pieces of legislation in attempts to nationalize the US's energy and to reduce greenhouse gas emissions in order to protect the environment. He cosponsored the Energy Independence and Security Act of 2007 "to move the United States toward greater energy independence and security, to increase the production of clean renewable fuels, to protect consumers, to increase the efficiency of products, buildings, and vehicles, to promote research on and deploy greenhouse gas capture and storage options, and to improve the energy performance of the Federal Government, and for other purposes." According to Larson, "I have become convinced of the need for comprehensive legislation to reduce the amount of greenhouse gases we are emitting into the environment." His stances on environmental protection have earned him a rating of 100% with the League of Conservation Voters.
== Pathophysiology == Since envenomation is completely voluntary, all venomous snakes are capable of biting without injecting venom into a person. Snakes may deliver such a "dry bite" rather than waste their venom on a creature too large for them to eat, a behaviour called venom metering. However, the percentage of dry bites varies among species: 80 percent of bites inflicted by sea snakes, which are normally timid, do not result in envenomation, whereas for pit viper bites the number is closer to 25 percent. Furthermore, some snake genera, such as rattlesnakes, can internally regulate the amount of venom they inject. There is a wide variance in the composition of venoms from one species of venomous snake to another. Some venoms may have their greatest effect on a victim's respiration or circulatory system. Others may damage or destroy tissues. This variance has imparted to the venom of each species a distinct chemistry. Sometimes antivenins have to be developed for individual species. For this reason, standard therapeutic measures will not work in all cases. Some dry bites may also be the result of imprecise timing on the snake's part, as venom may be prematurely released before the fangs have penetrated the person. Even without venom, some snakes, particularly large constrictors such as those belonging to the Boidae and Pythonidae families, can deliver damaging bites; large specimens often cause severe lacerations, or the snake itself pulls away, causing the flesh to be torn by the needle-sharp recurved teeth embedded in the person.
== GREAT Trust == The Gaza Reconstitution, Economic Acceleration and Transformation (GREAT) Trust is a proposed post-war reconstruction initiative for the Gaza Strip, outlined in a 38-page prospectus circulated within the Trump administration. The plan, which was devised by some of the same individuals behind the Gaza Humanitarian Foundation (GHF), is for a US-led multilateral trusteeship to govern Gaza after the disarmament of Hamas, transitioning from initial US-Israel bilateral control to broader international involvement, with Israel retaining overarching security rights. Its core goals are stated as redesigning Gaza's layout, economy, and governance and integrating it into the India–Middle East–Europe Economic Corridor (IMEC). Key components include 10 large projects under public-private partnerships (PPPs), such as rebuilding infrastructure (e.g., clearing unexploded ordnance and debris), highways and trams (e.g., the "MBS Ring" named after Saudi Crown Prince Mohammed bin Salman), an "Elon Musk Smart Manufacturing Zone" along the Gaza-Israel border, US-regulated data centers, a small port and airport, and luxury resorts with artificial islands. The plan would entail the "voluntary" temporary relocation of Gaza's 2 million+ population during reconstruction, with incentives like $5,000 per person cash bonuses, rent and food subsidies, and the assumption that 25% (about 500,000 people) would leave permanently. The plan has been criticized as a form of ethnic cleansing and forced displacement through a profit-driven exploitation.
Sources: en.wikipedia.org
== AFL career == Monfries was drafted by the Bombers with selection 14 in the 2004 AFL draft. He played football for Walkerville Junior Football Club before moving to Melbourne. He made his debut in Round 1, 2005 against Melbourne, which saw him become the 200th player to have played under coach Kevin Sheedy. Monfries maintained his position in the senior side until round 4, but was dropped for the Anzac Day clash in round 5, against Collingwood and did not play at senior level again until round 12. In round 13 against St Kilda, he kicked two goals and, alongside other young Bombers, played a role in a fifteen-point win. He then went on to play every game for the remainder of the season. In 2006, his second season, Monfries played 21 games, missing only one game due to a minor calf strain. In 2007, Monfries played 20 out of 22 games, omitted on form for two weeks at midseason. He was, however, named as an emergency for both matches and quickly returned to the team due to pressures caused by injuries and suspensions to other key players. In 2009, Monfries became a key player within the Essendon Football Club. He defined his role further as a key position forward and finished second in the club's goalkicking after Matthew Lloyd. On 5 October 2012, Angus told Essendon that he will be leaving and be signing a new four-year deal with Port Adelaide. On 8 October 2012, Essendon announced that Monfries would be traded to Port Adelaide for pick 48. He made his debut for Port Adelaide in round 1, 2013, against Melbourne.
== Lead optimization phase == The objective of this drug discovery phase is to synthesize lead compounds, new analogs with improved potency, reduced off-target activities, and physiochemical/metabolic properties suggestive of reasonable in vivo pharmacokinetics. This optimization is accomplished through chemical modification of the hit structure, with modifications chosen by employing knowledge of the structure–activity relationship (SAR) as well as structure-based design if structural information about the target is available. Lead optimization is concerned with experimental testing and confirmation of the compound based on animal efficacy models and ADMET (in vitro and in situ) tools that may be followed by target identification and target validation.
== Biography == Suzuki was born as the second son of a farmer in Haibara District, Shizuoka. He was a graduate of one of the predecessors of Tokyo Imperial University and subsequently worked as a research scientist at Riken. In 1901, he studied Peptide synthesis at the Humboldt University of Berlin under Emil Fischer. He returned to Japan in 1906, and accepted a post as professor of agricultural chemistry at Tokyo Imperial University in 1907. In 1910, Suzuki succeeded in extracting a water-soluble complex of micronutrients from rice bran and named it aberic acid, and which had the effect of curing patients of beriberi. He published this discovery in a Japanese scientific journal. When the article was translated into German, the translation failed to state that it was a newly discovered nutrient, a claim made in the original Japanese article, and hence his discovery failed to gain publicity. Polish biochemist Kazimierz Funk isolated the same complex of micronutrients and proposed the complex be named "vitamine" (from "vital amine") in 1912. In 1935, this compound was refined and correctly described as thiamine. On April 18, 1985, the Japan Patent Office selected him as one of Ten Japanese Great Inventors.
Clorazepate, sold under the brand name Tranxene among others, is a benzodiazepine medication. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. Clorazepate is an unusually long-lasting benzodiazepine and serves as a prodrug for the equally long-lasting desmethyldiazepam, which is rapidly produced as an active metabolite. Desmethyldiazepam is responsible for most of the therapeutic effects of clorazepate. It was patented in 1965 and approved for medical use in 1967.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.